Weill Cornell Medicine and New York Genome Center researchers, in collaboration with Oxford Nanopore Technologies, have developed a new method to assess on a large scale the three-dimensional structure of the human genome, or how the genome folds.
Dr. Laura Alonso, chief of the Division of Endocrinology, Diabetes and Metabolism and the Herbert J. and Ann L. Siegel Distinguished Professor of Medicine at Weill Cornell Medicine, has been selected to be a fellow of the Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program at Drexel University College of Medicine.
A multidisciplinary research program launched by Weill Cornell Medicine, the ILR School and Cornell Tech aims to elevate the value of home care workers while improving both their working conditions and their patients’ outcomes.
Dr. Sara Zaccara, a postdoctoral associate in the Department of Pharmacology at Weill Cornell Medicine, has won a 2022 Tri-Institutional Breakout Award for Junior Investigators.
A promising venture that hopes to develop a new drug therapy for colorectal cancer won $50,000 in funding and recognition from experienced venture capitalists on May 26 at the annual Biomedical Business Plan Challenge.
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, a type of blood cancer, and proved effective in animal models of the disease.
Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.
Mutations that drive cancer growth also make a cell more noticeable to the immune system, according to a study by investigators at Weill Cornell Medicine, Weill Cornell Graduate School of Medical Sciences and Memorial Sloan Kettering Cancer Center.
Weill Cornell Medicine faculty members were honored with awards for their exemplary achievements in medical research, education and care at the institution’s commencement ceremony on May 19 at Carnegie Hall.
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people with a mutation in a gene called SETD2, leading to a type of aggressive blood cancer.
The American Association of Neurological Surgeons (AANS) honored Dr. Roger Härtl, co-director of Och Spine at NewYork-Presbyterian and director of Weill Cornell Medicine’s Center for Comprehensive Spine Care, with its prestigious Humanitarian of the Year award.
More than 400 students celebrated a milestone on May 19: graduating from Weill Cornell Medical College and Weill Cornell Graduate School of Medical Sciences.
The award recognizes alumni for their outstanding contributions to biomedical research in education, focusing on science and scholarship, leadership, mentoring and teaching, and service to society.
The award honors an alumnus who has demonstrated outstanding achievement in research, education or patient care, and has brought acclaim to the institution.
New research led by investigators from Weill Cornell Medicine, Fred Hutchinson Cancer Center, University Hospitals Cleveland and Case Western Reserve University found that prostate cancer screening with the prostate specific antigen (PSA) blood test has remarkably favorable tradeoffs.
Dr. Denise Howard, a leading obstetrician and gynecologist who specializes in gynecologic surgery and women’s reproductive health, has been appointed chief of the Department of Obstetrics and Gynecology at NewYork-Presbyterian Brooklyn Methodist Hospital.
